Kerafast

Executive Summary

Kerafast is a Boston-based biotechnology company founded in 2011 that operates a global online marketplace for rare and unique biological research reagents. The company specializes in sourcing difficult-to-access materials—such as antibodies, cell lines, proteins, and viral vectors—directly from academic labs and research institutions. Its mission is to accelerate scientific discovery by improving the accessibility of specialized research tools developed in academia, effectively bridging the gap between academic innovation and commercial availability. By curating a catalog of over 10,000 products from hundreds of university labs worldwide, Kerafast enables researchers to obtain high-quality reagents that are typically not available through traditional suppliers. The platform handles logistics, quality control, and licensing, making it easier for academic inventors to distribute their discoveries while generating revenue for their labs. The market for research reagents is estimated at over $50 billion annually, with specialized and hard-to-find reagents representing a growing segment. Kerafast's unique model positions it as a key intermediary in the life sciences supply chain, benefiting from trends like open science and reproducibility. The company has likely achieved consistent growth by expanding its network of academic partners and customer base among biopharma and academic researchers. However, competition from larger distributors and the risk of IP disputes remain challenges. With no disclosed funding rounds, Kerafast appears to be bootstrapped or self-sustaining, which may limit growth speed but also indicates strong unit economics. Overall, Kerafast addresses a clear market need and has potential to capture a larger share of the specialized reagent market if it scales effectively.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a top-20 pharmaceutical company for exclusive access to academic reagents60% success
• Q2 2027Launch of a new product category (e.g., CRISPR tools or organoids) to expand addressable market50% success
• Q3 2026Series B funding round to accelerate platform development and sales team expansion70% success